Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma

BACKGROUND: In the new therapeutic era, comparisons between regimens containing lenalidomide and bortezomib are needed. METHODS: In this single‐center, prospective study, patients received four to six cycles of lenalidomide+liposomal doxorubicin+dexamethasone (RAD) or bortezomib+liposomal doxorubici...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Limei, Liu, Junru, Huang, Beihui, Kuang, Lifen, Gu, Jingli, Chen, Meilan, Zou, Waiyi, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940229/
https://www.ncbi.nlm.nih.gov/pubmed/33527753
http://dx.doi.org/10.1002/cam4.3762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940229/
https://www.ncbi.nlm.nih.gov/pubmed/33527753
http://dx.doi.org/10.1002/cam4.3762

Ejemplares similares